London, UK – [Current Date] – The landscape of chronic heart failure management in England is poised for a significant transformation following the National Institute for Health and Care Excellence (NICE) recommendation for Bayer’s groundbreaking non-steroidal drug, Kerendia (finerenone). This pivotal decision means that English patients suffering from chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF) will soon gain access to this innovative therapy, marking a crucial step forward in addressing one of the nation’s leading causes of avoidable hospitalisations.
n
The announcement signals a new era for a patient population that has historically faced limited effective treatment options. With the UK health watchdog’s final draft guidance expected in August 2026, healthcare providers and patients alike are looking forward to the integration of this next-generation mineralocorticoid receptor antagonist (MRA) into the National Health Service (NHS) formulary. This move is anticipated to not only enhance the quality of life for hundreds of thousands of individuals but also to alleviate some of the immense pressure on the NHS, which grapples with the substantial burden of heart failure-related admissions.
n
A New Horizon for Heart Failure Patients
n
Chronic heart failure (CHF) is a debilitating condition affecting millions globally, and a significant proportion of these patients fall into the categories of HFpEF and HFmrEF. Unlike heart failure with reduced ejection fraction (HFrEF), where the heart muscle is weakened and cannot pump enough blood, HFpEF and HFmrEF involve the heart muscle becoming stiff and unable to relax properly, impeding its ability to fill with blood. This distinction has historically presented a major challenge for pharmaceutical development, with fewer effective therapies available compared to HFrEF.
n
Kerendia, a highly selective, non-steroidal MRA, offers a novel approach to tackling the underlying pathophysiology of HFpEF and HFmrEF. Its mechanism of action targets multiple pathways implicated in the progression of heart failure, including reducing vascular inflammation and mitigating the mineralocorticoid signalling-induced scarring (fibrosis) in the muscular layer of the heart wall. Furthermore, finerenone helps to reduce sodium retention in the kidneys, which in turn diminishes the burden of pumping excess fluid on the already compromised heart. This multi-pronged attack on the disease process is what sets Kerendia apart and underpins its therapeutic promise.
n
The NICE recommendation is a culmination of extensive clinical research and rigorous evaluation, affirming Kerendia’s efficacy and cost-effectiveness. The drug’s non-steroidal nature is a key differentiator from older, steroidal MRAs like spironolactone and eplerenone, which have been mainstays in heart failure treatment but are often associated with a higher incidence of side effects, particularly hyperkalemia (elevated potassium levels) and, in the case of spironolactone, sexual side effects due to its less selective binding profile. Bayer’s design of Kerendia aimed for greater selectivity, meaning it interferes less with sex hormone activity, potentially leading to a lower rate of sexual side effects and a better safety profile overall. This improved tolerability is crucial for patient adherence and for expanding the eligible patient population, making it accessible to a wider demographic who might otherwise be unable to tolerate existing treatments.
n
Chronology of Kerendia’s Journey and Regulatory Milestones
n
The journey of Kerendia to this significant NICE recommendation has been marked by several key milestones, demonstrating its evolving role in clinical medicine.
n
2023: Initial NICE Approval for Chronic Kidney Disease (CKD)nKerendia first gained traction within the NHS in 2023, when NICE gave it the green light for use in adult patients with stage 3 or 4 chronic kidney disease linked to type 2 diabetes. This initial approval was contingent on the presence of albumin (a blood protein) in their urine, indicating kidney damage. This earlier recommendation underscored Kerendia’s beneficial effects beyond cardiovascular indications, particularly its renoprotective properties and its ability to reduce the risk of kidney failure and cardiovascular events in this vulnerable population. This prior approval established Kerendia’s safety and efficacy profile within the NHS system and laid the groundwork for its subsequent evaluation in heart failure.
n
March 2026: Expedited Regulatory PathwaysnJust months before this latest announcement, in March 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and NICE launched an aligned pathway designed to expedite the medicines regulation process. While Kerendia’s journey through the regulatory maze largely preceded the full implementation of this new pathway, its timely recommendation for heart failure underscores the UK’s commitment to bringing innovative therapies to patients faster. This new collaborative framework aims to streamline the assessment and approval of promising new drugs, ensuring that patients can benefit from scientific advancements without unnecessary delays.
n
August 2026: Anticipated Availability for Heart FailurenThe current recommendation for heart failure with preserved or mildly reduced ejection fraction is expected to culminate in Kerendia’s availability to English patients from August 2026. This timeline allows for the finalisation of guidance, procurement, and integration into clinical practice across the NHS. The anticipation surrounding its introduction highlights the significant unmet need that it addresses within the heart failure community.
n
Supporting Data: The Stark Reality of Heart Failure in England
n
The urgency behind the adoption of effective new treatments for heart failure is underscored by compelling statistics regarding the prevalence and impact of the condition across England.
n
NICE estimates that a staggering 635,000 patients across England are living with heart failure. A critical detail within this figure is that approximately half of these individuals suffer from heart failure with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF). This subtype has historically been challenging to treat, with symptoms ranging from debilitating breathlessness and fatigue to fluid retention, severely impacting patients’ quality of life and functional capacity.
n
The clinical and economic burden of heart failure is substantial. Between 2023 and 2024 alone, heart failure was linked to 100,000 hospitalisations in England. This figure firmly positions heart failure as one of the leading causes of avoidable hospital admissions, placing immense strain on NHS resources, including emergency departments, inpatient beds, and specialist cardiology services. These hospitalisations are not only costly to the healthcare system but also represent significant health setbacks for patients, often leading to a further decline in their condition, reduced independence, and increased mortality risk.
n
The introduction of Kerendia, therefore, is not merely about adding another drug to the formulary; it represents a strategic intervention aimed at mitigating these adverse outcomes. By effectively managing the disease progression and reducing the risk of acute decompensation, Kerendia holds the potential to significantly lower hospitalisation rates, thereby freeing up crucial NHS capacity and redirecting resources to other areas of need.
n
NICE’s assessment indicates that around 280,000 people across England are likely to be eligible for treatment with Kerendia for their heart failure. This substantial patient cohort highlights the widespread impact this recommendation will have, offering a new lease of life for many who previously had limited therapeutic options.
n
Official Responses and the Broader Treatment Landscape
n
The recommendation for Kerendia has been met with enthusiasm from health authorities, recognising its potential to reshape heart failure management.
n
Helen Knight, NICE’s director of medicines evaluation, articulated the dual benefits of this approval. She emphasised that Kerendia not only holds the potential to significantly boost patient quality of life by alleviating symptoms and reducing disease progression but also offers a tangible opportunity to "save the NHS money and free up space" by diminishing the risk of hospitalisation for unplanned emergency treatment. This statement underscores the strategic importance of innovative therapies that offer both clinical efficacy and economic value to a strained healthcare system. Reduced hospital admissions translate directly into lower treatment costs, fewer bed days, and improved resource allocation, allowing the NHS to operate more efficiently.
n
Kerendia will join an evolving arsenal of treatments available for heart failure patients in England. This includes established therapies and more recent innovations:
n
- n
- SGLT2 Inhibitors: Drugs like Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Forxiga (dapagliflozin) received NICE’s approval for CHF with preserved or mildly reduced ejection fraction back in 2023. These drugs have demonstrated significant benefits in reducing hospitalisations and improving outcomes for this patient group. Kerendia is expected to complement SGLT2 inhibitors, forming part of a comprehensive, multi-drug regimen often recommended for optimal heart failure management.
- Legacy MRAs: Older mineralocorticoid receptor antagonists such as spironolactone and eplerenone, developed by companies like Pfizer, have long been used in heart failure. However, Kerendia’s non-steroidal, more selective profile offers distinct advantages in terms of tolerability and applicability to a broader patient population, potentially leading to better adherence and long-term outcomes.
- Loop Diuretics: These medications continue to play a crucial role in managing fluid overload and symptomatic relief in heart failure patients. While not directly targeting disease progression, they remain vital for symptom control.
n
n
n
n
The addition of Kerendia provides clinicians with another powerful tool in their therapeutic armamentarium, enabling more personalised and effective treatment strategies for patients with HFpEF and HFmrEF. The modern approach to heart failure often involves a combination of drugs from different classes, each targeting a distinct pathological pathway, to achieve the best possible outcomes.
Implications: A Glimpse into the Future of Heart Failure Care
The NICE recommendation for Kerendia carries profound implications for patients, the NHS, and the broader pharmaceutical landscape in England.
For Patients: The most direct and significant impact will be on the lives of those living with HFpEF and HFmrEF. Access to Kerendia means a greater chance of reduced symptoms, improved functional capacity, and a lower risk of hospitalisation. This translates into a better quality of life, allowing patients to maintain independence, engage in daily activities, and experience fewer disruptions due to their chronic condition. The improved tolerability profile, particularly the reduced risk of sexual side effects compared to older MRAs, is also a crucial factor in enhancing patient experience and adherence to long-term treatment.
For the NHS: The potential for reduced hospitalisations offers a vital lifeline to an overburdened healthcare system. Each avoided admission frees up bed space, nursing time, and financial resources that can be reallocated to other critical areas. Over time, the cumulative effect of Kerendia’s widespread use could lead to significant cost efficiencies and a more sustainable model for heart failure care. Furthermore, by improving patient outcomes, the NHS can enhance its reputation for delivering high-quality, innovative care.
For Pharmaceutical Innovation: Kerendia’s success underscores the importance of continued research and development in areas of unmet medical need. It highlights the value of targeted therapies that address specific disease mechanisms, especially in complex conditions like heart failure where broad-spectrum treatments have often fallen short. The approval also reinforces Bayer’s position as a key player in cardiovascular medicine, demonstrating its commitment to bringing transformative medicines to market.
Challenges and Considerations: While the outlook is overwhelmingly positive, implementation will involve considerations. Healthcare providers will need comprehensive training on Kerendia’s appropriate use, monitoring requirements (e.g., potassium levels), and integration into existing treatment pathways. Patient education will also be crucial to ensure adherence and understanding of the benefits and potential side effects. Long-term real-world data will be invaluable in further solidifying Kerendia’s place in clinical practice.
In conclusion, the NICE recommendation for Kerendia represents a monumental step forward in the battle against chronic heart failure in England. By offering an innovative, well-tolerated, and effective treatment for a previously underserved patient population, Kerendia is set to significantly improve patient outcomes, alleviate pressure on the NHS, and usher in a new era of more comprehensive and targeted heart failure management. As England prepares for its availability in August 2026, there is a palpable sense of optimism for the future of cardiovascular health across the nation.
